Company news

Lucid Diagnostics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference

March 19, 2024

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024

March 11, 2024

Lucid Diagnostics Provides Update Regarding World Trade Center Health Program

February 15, 2024

Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony

February 14, 2024

Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors

February 7, 2024

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies

December 11, 2023

PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders

December 10, 2023

Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts

November 15, 2023

Lucid Diagnostics Provides Business Update and Third Quarter Financial Results

November 12, 2023

Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day

November 8, 2023

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2023

October 30, 2023

Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection

October 30, 2023

Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection

September 6, 2023

Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility of EsoGuard® Esophageal Precancer Detection in Fire Fighters

September 5, 2023

Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee Benefit

August 23, 2023

Lucid Diagnostics Provides Business Update and Second Quarter Financial Results

August 13, 2023

Lucid Diagnostics Launches First EsoGuard® Mobile Test Unit

June 4, 2023

Lucid Diagnostics Provides Business Update and First Quarter Financial Results

May 14, 2023

Lucid Diagnostics Reports Publication of Future Effective Foundational Local Coverage Determination by Medicare Administrative Contractor Noridian Healthcare Solutions

April 17, 2023

Lucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection of Esophageal Precancer and Cancer

March 30, 2023

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 14, 2023

March 2, 2023

Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results

November 13, 2022

Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer

November 8, 2022

Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results

August 14, 2022

Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio

August 10, 2022

Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements

August 1, 2022

Lucid Diagnostics to Hold a Business Update Conference Call on August 15, 2022

July 31, 2022

Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results

May 10, 2022

Lucid Diagnostics to Hold a Business Update Conference Call on May 11, 2022

April 24, 2022

Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination

April 3, 2022

Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results

March 27, 2022

Lucid Diagnostics to Hold a Business Update Conference Call on March 28, 2022

March 6, 2022

Lucid Diagnostics’ EsoGuard Esophageal DNA Test Wins “Diagnostics Innovation of the Year” Award

October 27, 2021

ADDING MULTIMEDIA Lucid Diagnostics Appoints Suman Verma MD, PhD as Chief Scientific Officer

October 20, 2021

Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering

October 17, 2021

Lucid Diagnostics Announces Pricing of Initial Public Offering

October 12, 2021

← Newer news releases

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.